Clinical trials: CLL
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
Healthy
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.
- Trial name
- NCT06787131
- Testing
- Rabeprazole 20 mg, Itraconazole (200 mg)
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Leukemia, Lymphocytic, Chronic
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding…
- Trial name
- NCT00076401
- Testing
- Motexafin gadolinium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
B-Cell Chronic Lymphocytic Leukemia
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00485966
- Testing
- CX-3543
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cylene Pharmaceuticals
Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor.
- Conditions
- Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT04279405
- Testing
- YY-20394
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Lymphocytic Leukemia, Chronic
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy.
- Trial name
- NCT02013817
- Testing
- rituximab [MabThera/Rituxan], fludarabine, cyclophosphamide
- Where
- 8 sites in Austria
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies…
- Conditions
- Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03547115
- Testing
- voruciclib monotherapy, voruciclib and venetoclax
- Where
- 12 sites in United States
- Volunteers
- 84 people
- Sponsor
- MEI Pharma, Inc.
Chronic Lymphocytic Leukemia
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
- Trial name
- NCT00073489
- Testing
- OSI-461
- Where
- 15 sites in United States
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)
- Trial name
- ULTRA-V (NCT03801525)
- Testing
- Ublituximab, Umbralisib, Venetoclax
- Where
- 50 sites in United States
- Volunteers
- 277 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell…
- Trial name
- FIRE (NCT03425591)
- Testing
- Ibrutinib
- Where
- France
- Volunteers
- 508 people
- Sponsor
- Janssen-Cilag Ltd.
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
- Conditions
- Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04305444
- Testing
- DTRM-555
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang DTRM Biopharma
Chronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06637501
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 32 sites in United States, Brazil and 4 more
- Volunteers
- 94 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus…
- Trial name
- NCT07277231
- Testing
- Sonrotoclax, Zanubrutinib, Acalabrutinib
- Where
- 115 sites in United States, Australia and 15 more
- Volunteers
- 500 people
- Sponsor
- BeOne Medicines
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL)…
- Conditions
- Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
- Trial name
- NCT00587457
- Testing
- CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
- Where
- 3 sites in United States, Poland
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Leukemia, B-cell, Lymphoma, B-Cell
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04649983
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd